Vincristine-induced peripheral neuropathy in pediatric cancer patients
- PMID: 27904761
- PMCID: PMC5126263
Vincristine-induced peripheral neuropathy in pediatric cancer patients
Abstract
Vincristine is a chemotherapeutic agent that is a component of many combination regimens for a variety of malignancies, including several common pediatric tumors. Vincristine treatment is limited by a progressive sensorimotor peripheral neuropathy. Vincristine-induced peripheral neuropathy (VIPN) is particularly challenging to detect and monitor in pediatric patients, in whom the side effect can diminish long term quality of life. This review summarizes the current state of knowledge regarding VIPN, focusing on its description, assessment, prediction, prevention, and treatment. Significant progress has been made in our knowledge about VIPN incidence and progression, and tools have been developed that enable clinicians to reliably measure VIPN in pediatric patients. Despite these successes, little progress has been made in identifying clinically useful predictors of VIPN or in developing effective approaches for VIPN prevention or treatment in either pediatric or adult patients. Further research is needed to predict, prevent, and treat VIPN to maximize therapeutic benefit and avoid unnecessary toxicity from vincristine treatment.
Keywords: Vincristine; assessment; pediatric oncology; peripheral neuropathy; pharmacogenetics; prevention.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/5126263/bin/ajcr0006-2416-f1.gif)
Similar articles
-
Vincristine-Induced Peripheral Neuropathy (VIPN) in Pediatric Tumors: Mechanisms, Risk Factors, Strategies of Prevention and Treatment.Int J Mol Sci. 2021 Apr 16;22(8):4112. doi: 10.3390/ijms22084112. Int J Mol Sci. 2021. PMID: 33923421 Free PMC article. Review.
-
The association between vincristine-induced peripheral neuropathy and health-related quality of life in children with cancer.Cancer Med. 2021 Nov;10(22):8172-8181. doi: 10.1002/cam4.4289. Epub 2021 Nov 1. Cancer Med. 2021. PMID: 34725942 Free PMC article.
-
Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy in Children with Cancer: A Systematic Review and Meta-Analysis.Cancers (Basel). 2022 Jan 26;14(3):612. doi: 10.3390/cancers14030612. Cancers (Basel). 2022. PMID: 35158880 Free PMC article. Review.
-
Vincristine-induced peripheral neuropathy in children with cancer: A systematic review.Crit Rev Oncol Hematol. 2017 Jun;114:114-130. doi: 10.1016/j.critrevonc.2017.04.004. Epub 2017 Apr 6. Crit Rev Oncol Hematol. 2017. PMID: 28477739 Review.
-
Prospective assessment of vincristine-induced peripheral neuropathy in paediatric acute lymphoblastic leukemia.Clin Neurophysiol. 2023 Oct;154:157-168. doi: 10.1016/j.clinph.2023.08.002. Epub 2023 Aug 11. Clin Neurophysiol. 2023. PMID: 37633123
Cited by
-
Evaluation of the Effect of Loratadine versus Diosmin/Hesperidin Combination on Vinca Alkaloids-Induced Neuropathy: A Randomized Controlled Clinical Trial.Pharmaceuticals (Basel). 2024 May 9;17(5):609. doi: 10.3390/ph17050609. Pharmaceuticals (Basel). 2024. PMID: 38794179 Free PMC article.
-
Identification of compounds that cause axonal dieback without cytotoxicity in dorsal root ganglia explants and intervertebral disc cells with potential to treat pain via denervation.PLoS One. 2024 May 2;19(5):e0300254. doi: 10.1371/journal.pone.0300254. eCollection 2024. PLoS One. 2024. PMID: 38696450 Free PMC article.
-
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.Eur J Med Res. 2024 Apr 9;29(1):224. doi: 10.1186/s40001-024-01822-7. Eur J Med Res. 2024. PMID: 38594732 Free PMC article. Review.
-
Without ENMG, detecting pediatric vincristine neuropathy is a challenge.Clin Neurophysiol Pract. 2024 Feb 14;9:94-101. doi: 10.1016/j.cnp.2024.01.005. eCollection 2024. Clin Neurophysiol Pract. 2024. PMID: 38440119 Free PMC article.
-
Netazepide, an Antagonist of Cholecystokinin Type 2 Receptor, Prevents Vincristine-Induced Sensory Neuropathy in Mice.Pharmaceuticals (Basel). 2024 Jan 23;17(2):144. doi: 10.3390/ph17020144. Pharmaceuticals (Basel). 2024. PMID: 38399359 Free PMC article.
References
-
- Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The Vinca Alkaloids: a New Class of Oncolytic Agents. Cancer Res. 1963;23:1390–1427. - PubMed
-
- Joel S. The comparative clinical pharmacology of vincristine and vindesine: does vindesine offer any advantage in clinical use? Cancer Treat Rev. 1996;21:513–525. - PubMed
Publication types
LinkOut - more resources
Full Text Sources